Fig 1.
Synthesis of BC-EDTA.
Fig 2.
Ultraviolet-Visible (UV) Absorption Spectrum of BC-EDTA.
Fig 3.
Outline of labeling bare particles with BC-EDTA.
Fig 4.
Scheme of labeling of antibody with BC-EDTA/Eu3+-nanosphere.
Fig 5.
Schematic representation of the immunoassay system for HBsAg by BC-EDTA/Eu3+-nanosphere.
Fig 6.
TEM of bare silica nanosphere.
Fig 7.
Relationship between fluorescence intensity of nanosphere and coating times.
BC-EDTA/Eu3+-nanosphere was diluted in 0.05 mol/L carbonate buffer, pH9.5, with the concentration of 0.01%.
Fig 8.
TEM of BC-EDTA/Eu3+-nanosphere.
Fig 9.
Excitation and Emission spectra of BC-EDTA/Eu3+ (A) and BC-EDTA/Eu3+-nanosphere (B).
(A) The concentration of BC-EDTA/Eu3+ is 10-3mol/L. The buffer was 0.05 mol/L carbonate buffer, pH9.5. (B) The concentration of BC-EDTA/Eu3+-nanosphere is 0.005%. The buffer was 0.05 mol/L carbonate buffer, pH9.5.
Table 1.
Unspecific conjugation of antibody labeled BC-EDTA/Eu3+-nanosphere, unlabeled BC-EDTA/Eu3+-nanosphere to antibody coated microwell plate.
Table 2.
Specific conjugation of antibody labeled BC-EDTA/Eu3+-nanosphere to HBsAg coated mircowell plate.
Table 3.
Functional sensitivity of BC-EDTA/Eu3+-nanosphere.
Table 4.
Analytical precision of determination of HBsAg in human serum (n = 20).
Table 5.
Analytical recovery rate of determination of HBsAg in human serum (n = 10).
Fig 10.
Calibration curves for HBsAg.
Fig 11.
Regression analysis result of BC-EDTA/Eu3+-nanosphere based TrFIA and DELFIA.